Effects of asialo-erythropoietin on pain-related behavior and expression of phosphorylated-p38 map kinase and tumor necrosis factor-alpha induced by application of autologous nucleus pulposus on nerve root in rat

Spine

Volumn 36, Issue 2, 2011, Pages

  Sasaki, Nobuyuki ^a   Sekiguchi, Miho ^a   Kikuchi, Shin Ichi ^a   Konno, Shin Ichi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Asialo erythropoietin; erythropoietin; lumbar disc herniation; p38 mitogen activated kinase; tumor necrosis factor alpha

Indexed keywords

ASIALO ERYTHROPOIETIN; ERYTHROPOIETIN; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUMBAR DISK HERNIA; NERVE ROOT; NEUROPROTECTION; NONHUMAN; NUCLEUS PULPOSUS; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE; STUDENT T TEST;

ANIMALS; ASIALOGLYCOPROTEINS; BEHAVIOR, ANIMAL; ERYTHROPOIETIN; FEMALE; GANGLIA, SPINAL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK DISPLACEMENT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PAIN; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; TRANSPLANTATION, AUTOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79551514786     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181f137a8     Document Type: Article

References (54)

1. Aoki Y, Rydevik B, Kikuchi S, et al. Local application of disc-related cytokines on spinal nerve roots. Spine 2002;27:1614-17.
2. Igarashi T, Kikuchi S, Shubayev V, et al. Exogenous tumor necrosis factor alpha mimics nucleus pulposus-induced neuropathology: molecular, histologic, and behavioral comparisons in rats. Spine 2000;25:2975-80.
3. Olmarker K, Blomquist J, Stromberg J, et al. Infl ammatogenic properties of nucleus pulposus. Spine 1995;20:665-9.
4. Olmarker K, Larsson K. Tumor necrosis factor alpha and nucleuspulposus induced nerve root injury. Spine 1998;23:2538-44.
5. Olmarker K, Rydevik B, Nordborg C. Autologous nucleus pulposus induces neurophysiologic and histologic changes in porcine cauda equina nerve roots. Spine 1993;18:1425-32.
6. Rand N, Reichert F, Floman Y, et al. Murine nucleus pulposus- derived cells secrete interleukins-1-beta, -6, and -10 and granulocyte- macrophage colony-stimulating factor in cell culture. Spine 1997;22:2598-601.
7. Murata Y, Nannmark U, Rydevik B, et al. Nucleus pulposus- induced apoptosis in dorsal root ganglion following experimental disc herniation in rats. Spine 2006;31:382-90.
8. Murata Y, Onda A, Rydevik B, et al. Distribution and appearance of tumor necrosis factor-alpha in the dorsal root ganglion exposed to experimental disc herniation in rats. Spine 2004;29:2235-41.
9. Murata Y, Nannmark U, Rydevik B, et al. The role of tumor necrosis factor-alpha in apoptosis of dorsal root ganglion cells induced by herniated nucleus pulposus in rats. Spine 2008;33:155-62.
10. Sasaki N, Kikuchi S, Konno S, et al. Anti-TNF-alpha antibody reduces pain-behavioral changes induced by epidural application of nucleus pulposus in a rat model depending on the timing of administration. Spine 2007;32:413-16.
11. Murata Y, Onda A, Rydevik B, et al. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced histologic changes in the dorsal root ganglion. Spine 2004;29:2477-84.
12. Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor- alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implication for future pharmacologic treatment strategies of sciatica. Spine 2001;26:863-9.
13. Kato K, Kikuchi S, Shubayev VI, et al. Distribution and tumor necrosis factor-alpha isoform binding specifi city of locally administered etanercept into injured and uninjured rat sciatic nerve. Neuroscience 2009;160:492-500.
14. Myers RR, Sekiguchi Y, Kikuchi S, et al. Inhibition of p38 MAP kinase activity enhances axonal regeneration. Exp Neurol 2003;184:606-14.
15. Ito T, Ohtori S, Inoue G, et al. Glial phosphorylated p38 MAP kinase mediates pain in a rat model of lumbar disc herniation and induces motor dysfunction in a rat model of lumbar spinal canal stenosis. Spine 2007;32:159-67.
16. Lee JC, Kassis S, Kumar S, et al. p38 mitogen-activated protein kinase inhibitors-mechanism and therapeutic potentials. Pharmacol Ther 1999;82:389-97.
17. Schafers M, Svensson CI, Sommer C, et al. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003; 23:2517-21.
18. Roulston A, Reinhard C, Amiri P, et al. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 1998;273:10232-9.
19. Jun CD, Pae HO, Kwak HJ, et al. Modulation of nitric oxideinduced apoptotic death of HL-60 cells by protein kinase C and protein kinase A through mitogen-activated protein kinases and CPP32-like protease pathways. Cell Immunol 1999;194:36-46.
20. Marti HH, Bernaudin M, Petit E, Bauer C. Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol Sci 2000;15:225-9.
21. Kawakami M, Sekiguchi M, Sato K, et al. Erythropoietin receptormediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001;276:39469-75.
22. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000;97:10526-31.
23. Taoufi k E, Petit E, Divoux D, et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury. Proc Natl Acad Sci U S A 2008;105:6185-90.
24. Santhanam AV, Katusic ZS. Erythropoietin and cerebral vascular protection: role of nitric oxide. Acta Pharmacol Sin 2006;27:1389-94.
25. Celik M, Gökmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 2002;99:2258-63.
26. Campana WM, Myers RR. Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. Eur J Neurosci 2003;18:1497-506.
27. Campana WM, Li X, Shubayev VI, et al. Erythropoietin reduces Schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury. Eur J Neurosci 2006;23: 617-26.
28. Meloni BP, Tilbrook PA, Boulos S, et al. Erythropoietin preconditioning in neuronal cultures: signaling, protection from in vitro ischemia, and proteomic analysis. J Neurosci Res 2006;83:584-93.
29. Bianchi R, Buyukakilli B, Brines M, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A 2004;101:823-8.
30. Sekiguchi Y, Kikuchi S, Myers RR, et al. ISSLS prize winner: erythropoietin inhibits spinal neuronal apoptosis and pain following nerve root crush. Spine 2003;28:2577-84.
31. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci New York, NY, USA 1998;95:4635-40.
32. Ahmet H. Erythropoietin and the Nervous System: Novel Therapeutic Options for Neuroprotection. New York, NY: Springer-Verlag; 2005.
33. Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004;22:105-19.
34. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005;6:484-94.
35. Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 2003;100:6741-6.
36. Mennini T, De Paolo M, Bigini P, et al. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 2006;12:153-60.
37. Grasso G, Sfacteria A, Erbayraktar S, et al. Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. J Neurosurg Spine 2006;4:310-18.
38. Otoshi K, Kikuchi S, Konno S, et al. The reaction of glial cells and endoneurial macrophages in the dorsal root ganglion and their contribution to pain-related behavior after application of nucleus pulposus onto the nerve root in rats. Spine 2010;35:10-17.
39. Jin SX, Zhuang ZY, Woolf CJ, et al. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 2003;23:4017-22.
40. Obata K, Yamanaka H, Kobayashi K, et al. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J Neurosci 2004;24:10211-22.
41. Tachihara H, Sekiguchi M, Kikuchi S, et al. Do corticosteroids produce additional benefi t in nerve root infi ltration for lumbar disc herniation? Spine 2008;33:743-7.
42. Jia H, Feng X, Li W, et al. Recombinant human erythropoietin attenuates spinal neuroimmune activation of neuropathic pain in rats. Ann Clin Lab Sci 2009;39:84-91.
43. Jia HB, Jin Y, Ji Q, et al. Effects of recombinant human erythropoietin on neuropathic pain and cerebral expressions of cytokines and nuclear factor-kappa B. Can J Anaesth 2009;56:597-603.
44. Dong YJ, Kung C, Goldwasser E. Receptor binding of asialoerythropoietin. J Cell Biochem 1992;48:269-76.
45. Park JG, Yuk Y, Rhim H, et al. Role of p38 MAPK in the regulation of apoptosis signaling induced by TNF-alpha in differentiated PC12 cells. J Biochem Mol Biol 2002;35:267-72.
46. Zhuang ZY, Wen YR, Zhang DR, et al. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 2006;26:3551-60.
47. Takahashi N, Kikuchi S, Shubayev V, et al. TNF-alpha and phosphorylation of ERK in DRG and spinal cord. Spine 2006;31: 523-9.
48. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-7.
49. Kilic U, Kilic E, Soliz J. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J 2005;19:249-51.
50. Nagata Y, Todokoro K. Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood 1999;94:853-63.
51. Nagata Y, Takahashi N, Davis RJ, et al. Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood 1998;92:1859-69.
52. Lee SM, Nguyen TH, Park MH, et al. EPO receptor-mediated ERK kinase and NF-kappaB activation in erythropoietin-promoted differentiation of astrocytes. Biochem Biophys Res Commun 2004;320:1087-95.
53. Okada T, Sawada T, Kubota K. Asialoerythropoietin has strong renoprotective effects against ischemia-reperfusion injury in a murine model. Transplantation 2007;84:504-10.
54. Wang X, Zhu C, Wang X, et al. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 2004;91:900-10.